干扰素不同给药方法治疗宫颈SPI的临床研究

目的探讨干扰素不同给药方法治疗宫颈人乳头瘤病毒亚临床感染（简称宫颈SPI）的疗效和不良反应。方法将经阴道镜和宫颈活检组织病理学诊断为宫颈SPI的42例患者,采取随机双盲法分为A组和B组。A组给予干扰素栓塞阴道治疗,B组给予皮下注射干扰素治疗,观察两组患者治疗前、后阴道镜下的宫颈情况、HPV病毒转阴率和药物不良反应等。结果 A组、B组的总有效率分别为85.7%、90.5%（P〉0.05）,HPV病毒转阴率分别为76.2%、81.0%（P〉0.05）。结论干扰素两种不同给药方法治疗宫颈SPI的疗效显著,能提高HPV病毒转阴率,临床上可视患者情况选择适宜的给药方法。     

匹多莫德联合微波治疗尖锐湿疣的临床观察

目的观察匹多莫德联合微波治疗尖锐湿疣的临床疗效。方法选择门诊尖锐湿疣患者70例,随机分为治疗组38例和对照组32例,所有患者均用微波去除疣体,治疗组口服匹多莫德,对照组肌注a-2b干扰素。结果治疗组复发率13．16％,对照组复发率55．88％,两组复发率比较有显著性差异（P〈0．05）。结论匹多莫德联合微波治疗尖锐湿疣的疗效确切。     

匹多莫德口服液联合舒利迭治疗老年支气管哮喘的临床观察

目的观察匹多莫德口服液联合舒利迭治疗老年支气管哮喘的临床疗效。方法选择老年支气管哮喘病人41例,按用药不同,将其分为两组:实验组21例,对照组20例,两组均给予持续吸氧、抗炎、解痉、平喘、止咳、祛痰等常规综合治疗。实验组在此基础上加用匹多莫德口服液14 ml,2次/d,口服,连续服用2~3个月后,停1~2个月后再服用2~3个月,按此规律持续1年左右。同时给予舒利迭粉吸入剂50/500μg吸入,2次/d,哮喘发作时每次2吸,缓解期每次1吸,长期应用。比较两组的临床疗效和治疗3个月后肺功能改善情况。结果实验组的总有效率为76.2%。对照组的总有效率为45.0%。两组比较差异有统计学意义(P<0.05)。实验组患者在治疗3个月后的第1秒用力呼气容积占预计值百分比以及呼气峰流速变异率与对照组比较,差异均有统计学意义(P<0.05)。结论匹多莫德口服液联合舒利迭吸入治疗老年支气管哮喘疗效显著。     

干扰素联合光动力治疗慢性宫颈炎合并持续性HPV感染的疗效

目的探讨重组人干扰素-α2b(Recombinant human interferon alpha 2b, rhIFN-α2b)联合5-氨基酮戊酸(5-Aminolevulinic acid,ALA)-光动力疗法(photodynamic therapy,PDT)治疗对慢性宫颈炎合并持续人乳头瘤病毒(Human Papillomavirus,HPV)感染患者血清转化生长因子β1(transforming growth factor-β1,TGF-β1)与白细胞介素10(Interleukin-10,IL-10)的影响。方法感染HPV的慢性宫颈炎患者102例,按照数字随机表法分为观察组和对照组,每组患者51例。对照组采用rhIFN-α2b治疗;观察组采用rhIFN-α2b联合ALA-PDT治疗,PDT治疗功率密度80 mW/cm~2,照射时间20～60 min,能量密度150 J/cm~2,共治疗3次,每次治疗间隔7 d。采用qRT-PCR法分别对治疗前、治疗后1和3个月的HPV-DNA负荷量进行检查,并分析治疗后3个月的转阴率;采用酶联免疫法在治疗后1个月分别对两组患者血清中TGF-β1、IL-10蛋白水平进行检测。结果治疗后1和3个月观察组患者HPV-DNA负荷量低于对照组(P0. 05);观察组转阴率(80. 4%)高于对照组(58. 8%)(P0. 05);观察组患者血清中TGF-β1、IL-10水平均明显低于对照组,差异具有统计学意义(P0. 05)。结论 rhIFN-α2b联合ALA-PDT能降低慢性宫颈炎合并持续HPV感染可降低患者血清中TGF-β1、IL-10水平,可减少宫颈癌发生率的风险。     

甲硝唑泡腾片联合重组人干扰素α-2a栓治疗宫颈糜烂的临床效果观察

目的探讨甲硝唑泡腾片联合重组人干扰索α-2a栓治疗宫颈糜烂的疗效。方法选择2010年1月-2012年10月8月在我院生育保健普查和两癌普查中确诊为宫颈糜烂患者600例,均予以甲硝唑泡腾片联合重组人干扰索α-2a栓治疗,3个疗程后进行疗效判定。结果 600例患者中,轻度糜烂总有效率为88.1%,中度糜烂总有效率为85.7%,重度糜烂总有效率为73.9%。轻、中度糜烂治愈率明显高于重度,差异性显著(P<0.05),轻、中度糜烂治愈率无显著差异(P>0.05)。结论甲硝唑泡腾片联合重组人干扰素α-2a栓治疗宫颈糜烂疗效好,且方便又安全。     

脾氨肽口服冻干粉联合匹多莫德口服液治疗小儿反复呼吸道感染效果分析

目的：观察分析应用脾氨肽口服冻干粉联合匹多莫得口服液对于小儿反复呼吸道感染进行治疗的临床效果。方法选择收治的该类患者作为研究对象并进行分组治疗,对照组应用常规方式进行治疗,治疗组在对照组的基础上给予脾氨肽口服冻干粉联合匹多莫德口服液进行治疗,将两组患者的总有效率、症状表现、体征变化以及免疫学检查结果进行比较分析。结果治疗组患者总有效率高达92.0％,显著高于对照组的41.3％;治疗组患者的发热、扁桃体肿大、肺内啰音等症状消退时间均显著短于对照组;对照组T细胞亚群CD4＋显著高于对照组,CD8＋显著低于对照组,上述差异具有统计学意义（ P＜0.05）。结论应用脾氨肽口服冻干粉联合匹多莫德口服液对于小儿反复呼吸道感染进行治疗,可以取得较好的临床疗效,具有极大的推广应用价值。     

异维A酸联合重组人干扰素α-2b治疗复发性尖锐湿疣(附48例分析)

目的:观察总结异维A酸联合重组人干扰素α-2b在治疗复发性尖锐湿疣中的作用.方法:48例中,男39例,女9例,45例通过取疣组织作涂片用帕氏(PaPanicolaou)染色确诊,3例通过免疫组化法确诊,其中1例通过PCR、HPV、DNA扩增进一步证实.患者口服异维A酸胶丸(上海延安药业有限公司生产)10 mg,2次/d;同时给予重组α-2b干扰素300万u,每晚睡前肌注1支,口服扑热息痛1片,连注射15次以后改为隔日1次,连用4个月(期间停用扑热息痛片).结果:异维A酸联合重组人干扰素α-2b治疗复发性尖锐湿疣总有效率79.2%.结论:异维A酸联合重组人干扰素α-2b治疗复发性尖锐湿疣具有较高的推广价值.     

贺普丁联合干扰素治疗慢性乙型肝炎30例报告

目的:观察贺普丁联合重组人干扰素a-2b治疗慢性乙型肝炎的临床效果.方法:治疗组用贺普丁0.1 g,口服每天一次,最少二年,重组人干扰素a-2b500万U肌注,隔日一次,共六个月;对照组:单用干扰素,方法及剂量与治疗组相同.结果:治疗组HBeAg转阴及HBeAb转阳显著优于单用干扰素组.随访1年后,联合治疗组疗效持久,HBV-DNA和HBeAg持该阴性.结论:贺普丁联合干扰素是一种安全有效的治疗慢性乙型肝炎方案.     

重组人干扰素α-1b联合拉米夫定治疗HBeAg阳性慢性乙型肝炎疗效分析

目的分析重组人干扰素α-1b和加用拉米夫定治疗HBeAg阳性慢性乙型肝炎患者的疗效和安全性,分析不同因素对疗效的影响,探索慢性乙型肝炎患者联合抗病毒治疗方法的优点。方法选择HBeAg阳性慢性乙型肝炎患者111例,随机分为治疗组和对照组。治疗组62例给予重组人干扰素α-1b（50μg/次,隔日1次,肌肉注射）加拉米夫定（100mg/d,口服）,疗程为6～12个月或12个月以上。对照组49例给予重组人干扰素α-1b单药治疗（方法同前）。结果①治疗组12和18个月HBeAg血清学转换率分别为29.03%和38.71%;对照组12和18个月HBeAg血清学转换率分别为28.57%和36.73%,两组比较差异无统计学意义。②治疗组6、12、18个月的HBVDNA低于检测下限率分别为66.13%、83.87%和88.71%,对照组为8.16%、53.06%和57.14%;两组比较差异具有统计学意义。③性别、年龄对HBeAg血清学转换率无影响,治疗前HBVDNA〈6log10拷贝/ml者HBeAg血清转换率较高。④重组人干扰素α-1b组发热及血象异常发生率分别为32.26%和27.42%,对照组分别为36.73%和34.69%,两组差异无统计学意义。结论重组人干扰素α-1b联合拉米夫定治疗HBeAg血清学转换率与单用重组人干扰素α-1b无明显差异,但HBVDNA低于检测下限率明显高于单用重组人干扰素α-1b组。拉米夫定的耐药率明显降低。     

联合α-2b干扰素治疗阿德福韦酯治疗早期慢性乙肝患者的疗效观察

目的：观察阿德福韦酯治疗半年应答欠佳的患者,联合应用α-2b干扰素治疗的疗效。方法：选择2010年7月-2013年7月就诊的,已予阿德福韦酯口服治疗半年应答欠佳的HBeAg阳性的慢性乙肝患者,分为两组共60例,治疗组30例,予α-2b干扰素联合阿德福韦酯治疗12个月,对照组予阿德福韦酯单药治疗12个月,观察治疗前及治疗后3个月、6个月、12个月患者的ALT水平、HBV—DNA水平,乙肝病毒血清标志物的变化。结果：治疗组在治疗后3个月、6个月、12个月时HBV—DNA转阴率、HBeAg转阴率、HBeAg转换率,两组之间的差异（P〈0．05）有统计学意义。结论：阿德福韦酯治疗早期应答欠佳的患者联合应用α-2b干扰素治疗后可获得较好的临床疗效。     

Efficacy of photodynamic therapy with 5-aminolevulinic acid for the treatment of cervical high-grade squamous intraepithelial lesions with high-risk HPV infection: A retrospective study

BackgroundThe current principle of clinical management of cervical high-grade squamous intraepithelial lesion(HSIL) is surgical excision. However excisional procedures of the uterine cervix may have a negative impact on fertility. Topical photodynamic therapy(PDT) is a non-invasive and selective tissue destruction. We investigated the clinical efficacy of PDT for cervical HSIL with high-risk human papilloma virus(HPV) infection.MethodsA retrospective study consisting of 96 patients aged 20–50 years with a histologically confirmed cervical HSIL with high-risk HPV infection from July 2018 to June 2022 was carried out. Patients were treated with six times of 20% 5-aminolevulinic acid photodynamic therapy (5-ALA PDT) at intervals of 7–14 days. Three months after treatment, the effect was evaluated through HPV typing and colposcopy directed biopsy. Six and twelve months after treatment, TCT and HPV tests were carried out.ResultsThree months after 5-ALA PDT treatment, among 96 HSIL with high-risk HPV infection patients, the total lesion regression rate was 89.58%(86/96), and the HPV clearance rate was 79.17 % (76/96) at 3 months follow-up. At 6 and 12 months follow-up, the patients who was HSIL pathological regression and negative HPV at 3 months follow-up continued negative results in both TCT and HPV. All patients with ineffective 5-ALA PDT treatment had persistent HPV infections. There was no significant difference in the HSIL regression rate and HPV clearance rate among different age groups. The main side effects of PDT were abdominal pain and increased vaginal secretions. Univariate analysis showed that the different severity of cervical cytology was associated with lesion regression rate in 5-ALA PDT treatment. The HSIL regression rate of TCT<ASC-H was higher than that of TCT≧ASC-H(94.59% vs 72.72%; P<0.01).Multicentric lesions,the proportion of visible lesion size in ectocervical size≥24.59%, size of visible lesion ≥1.23cm² and maximum linear length of visible lesion ≥0.90cm were risk factors of HSIL persistence after 5-ALA PDT treatment (P<0.05).Conclusion5-ALA PDT can be a safe and efficient treatment for cervical HSIL who wish to preserve fertility. 5-ALA PDT did not appear to create cervical damage and have negligible side effects. But we need evaluate the type of transformation zone, the visible lesion size, the location of lesion,baseline status of TCT and histological results before 5-ALA PDT treatment.     

Evaluation of the efficacy and safety of 5-aminolevulinic acid-mediated photodynamic therapy in women with high-risk HPV persistent infection after cervical conization

ObjectiveTo evaluate the efficacy and safety of photodynamic therapy (PDT) in women with high-risk human papillomavirus (hr-HPV) persistent infection after cervical conization, including loop electrosurgical excision procedure (LEEP) and cold knife conization (CKC).Materials and methodsThe clinicopathological and follow-up data of 76 women with hr-HPV persistent infection after cervical conization (54 cases with LEEP and 22 cases with CKC) were collected. All the women in this group met these criteria: postoperative pathological diagnosis of LEEP/CKC showed high grade squamous intraepithelial lesions (HSIL) with negative incisal margin, hr-HPV persistent infection after LEEP/CKC ≥ 1 year, colposcopy and histopathology showed no intraepithelial lesions before PDT, and 5-aminolaevulinic acid (5-ALA) as photosensitizer treating for 6 times with an interval of 7-10 days. The above patients were followed up 6 months and 12 months after PDT, and the follow-up contents included Roche Cobas HPV classification test, cytology, colposcopy, and pathological examinations. HPV negative conversion rate is an index to evaluate the efficacy of PDT. In addition, we also assessed the safety of PDT.ResultsSix months after PDT, the overall HPV clearance rate was 59.21% (45/76). The HPV negative conversion rates in patients ≤ 50 years old group and > 50 years old group were 68.52% (37/54) and 36.36% (8/22), respectively (P=0.009). But there was no significant difference in HPV clearance rate between the HPV16/18 infection group and other hr-HPV infection group (P=0.3326). 12 months after PDT, 1 case underwent hysterectomy because of progression to HSIL, and 7 cases lost follow-up. The overall HPV clearance rate was 88.24% (60/68). The negative conversion rates of HPV16/18 and other hr-HPV infection groups were 76.00% (19/25) and 95.35% (41/43), respectively (P=0.0458). However, the HPV negative conversion rate was not correlated with the patient's age (P=0.2383). The adverse reactions after PDT were mild, mainly manifested as increased vaginal secretions or burning/tingling.ConclusionsPhotodynamic therapy could be an effective treatment for patients with hr-HPV persistent infection after cervical conization and it could promote the negative conversion of hr-HPV and prevent the recurrence progression of cervical intraepithelial neoplasia (CIN) after LEEP/CKC.     

Evaluation of 5-aminolevulinic acid-mediated photodynamic therapy in postmenopausal women with persistent HPV infection with or without cervical and vaginal low-grade squamous intraepithelial lesions (CIN1/VaIN1)

ObjectiveTo analyze the efficacy and safety of photodynamic therapy (PDT) on postmenopausal women with persistent human papillomavirus (HPV) infection with or without low-grade cervical and vaginal intraepithelial neoplasia (CIN1 and VaIN1).Materials and methodsThe clinicopathological and follow-up data of 86 postmenopausal women with HPV infection (35 cases with chronic cervicitis and 51 cases with CIN1/VaIN1) were collected. All the women in this group met these criteria: menopausal time ≥ 1 year, HPV infection time ≥ 2 years, colposcopy and pathological diagnosis of biopsy ≤ CIN1/VaIN1 before PDT treatment, and 5-aminolaevulinic acid (5-ALA) as photosensitizer treating for 6 times with a week interval. The above patients were followed up 6 months and 12 months after PDT treatment, and the follow-up contents included HPV typing, cytology, colposcopy and pathological examinations. HPV negative conversion rate and lesion remission rate are the evaluation indicators of treatment efficacy. In addition, we also assessed the safety of PDT treatment.ResultsAt 12-month follow-up, the overall HPV clearance rate was 60% (45/75), of which the negative conversion rate of 16/18 HPV was 41.38% (12/29), and non-16/18 HPV was 71.74% (33/46) (p = 0.009). In patients without lesions, the HPV clearance rate was 51.72% (15/29), while in patients with CIN1/VaIN1 (n = 46), the HPV complete remission rate and lesion regression rate were 65.22% (30/46) and 89.13% (41/46), respectively. In addition, the clearance rate of HPV in lesion regression group was significantly higher than that in lesion persistence/progression group (0.00% vs. 73.17%, p = 0.003). The adverse reactions after PDT treatment were mild, mainly manifested as increased vaginal secretions or burning/tingling.ConclusionsPhotodynamic therapy can significantly enhance the elimination rate of persistent HPV infection in postmenopausal women and reduce the progression of CIN1/VaIN1. It could be an effective conservative treatment for persistent HPV infection and CIN1/VaIN1 in postmenopausal women.     

Topical photodynamic therapy with 5-aminolevulinic acid for cervical high-risk HPV infection

ObjectiveTo investigate the clinical efficacy of 5-aminolevulinic acid photodynamic therapy (ALA–PDT) for cervical high-risk HPV (HR-HPV) infection.MethodsIn this prospective study, a total of 76 patients with persistent cervical HR-HPV infection were randomly divided into two groups. The treatment group (39 patients) received three treatments of ALA–PDT at two-week intervals. The control group (37 patients) received no treatment. All patients were followed up for 9 months. Hybrid Capture HPV DNA Assay and ThinPrep cytology test (TCT) were performed for both groups. Patients with abnormal TCT results received colposcopic biopsy before treatment and during follow-ups.ResultsHR-HPV remission rates were 64.10% (25/39) in the treatment group and 24.32% (9/37) in the control group at 3 month follow-up. Complete remission rates were 76.92% (30/39) and 32.40% (12/37), respectively, in the two groups at 9 month follow-up. There was a statistically significant difference between the two groups (P < 0.01). Conversion rates of abnormal TCT results were 81.81% (9/11) in the treatment group and 12.50% (1/8) in the control group at 3 months, and 90.90% (10/11) and 25.00% (2/8), respectively, at 9 months. Five of six patients with CIN I in the treatment group and no patients in the control group achieved complete response at 9 months. There was a statistically significant difference between the two groups (P < 0.01).ConclusionTopical ALA–PDT is an effective, safe and well tolerated treatment for cervical HR-HPV infection.     

Effects of photodynamic therapy in the treatment of high-grade vaginal intraepithelial lesions following hysterectomy and HPV infection

BackgroundNon-invasive treatment therapy, such as 5-Aminolevulinic acid photodynamic therapy (ALA-PDT), has gained attention for its effect on select cervical and vaginal lesions. To investigate the effect of ALA-PDT on high-grade vaginal intraepithelial lesions (HG VAIN) after hysterectomy and high-risk human papillomavirus (HR-HPV) infection, in this study, we evaluated the clinical efficacy and safety of ALA-PDT in 23 patients with HG VAIN following hysterectomy and HPV.Methods23 patients with HG VAIN after hysterectomy were selected for photodynamic therapy, and the therapeutic effect, adverse reactions, recurrence rate and HPV clearance rate were analyzed respectively. The patients were followed up at 3, 6, 9, and 12 months after ALA-PDT. HPV, thinprep cytologic test (TCT) and reid colposcopic index (RCI) score should be performed 3 months after treatment. When the RCI score is higher than or equal to 3, a colposcopy biopsy should be conducted, the additional ALA-PDT should be continued if residual lesions were detected. When the RCI score is lower than or equal to 2, HPV and TCT should be reviewed every 3 months.ResultsAfter 3 months of photodynamic therapy, 21 patients were cured, with the cure rate of 91.3% (21/23). Two patients (8.7%) had residual lesions, which had degraded compared with the previous. After treatment, the overall HR-HPV clearance rate was 56.5% at 3 months, 65.2% at 6 months, 69.5% at 9 months, and 74% at 12 months. No obvious adverse reactions were found during and after treatment. Moreover, no recurrence occurred during the whole follow-up period.ConclusionsCompared with other therapies, ALA-PDT is a novel therapy with non-invasive procedure in HG VAIN after hysterectomy. ALA-PDT can be used for the treatment of HG VAIN after hysterectomy, moreover, it can not only effectively clear HR-HPV, but also can prevent the recurrence and progression of vaginal lesions caused by persistent HR-HPV infection.     

人乳头瘤病毒检测在宫颈疾病诊断中的意义

目的探讨人乳头瘤病毒(HPV)检测在宫颈疾病诊断中的应用及临床意义。方法选取2009年5月—2010年11月520例在大连医科大学附属一院三部妇科就诊妇女为研究对象,取宫颈脱落细胞采用导流杂交基因芯片(HybriMax)法行HPV检测,同时结合组织病理学检查进行分析,明确HPV感染与宫颈疾病的关系及宫颈癌的发生、发展过程。结果 HPV总感染率为48.8%,30～39岁年龄组HPV感染率最高为54.5%;组织病理学诊断慢性宫颈炎症、低级别病变(CINⅠ)、高级别病变(CINⅡ～Ⅲ)、宫颈原位癌或浸润癌中高危HPV感染检出率以42.2%、65.8%、95.4%、100.0%依次递增。结论宫颈疾病与高危型HPV感染有着十分密切的关系,引起宫颈肿瘤的最主要原因是高危型HPV感染,高危型HPV检测可作为宫颈癌的一种重要筛查手段。     

Evaluation of 5-aminolevulinic acid-mediated photodynamic therapy on cervical low-grade squamous intraepithelial lesions with high-risk HPV infection

BackgroundThe treatment options for low‐grade squamous intraepithelial neoplasia (LSIL) of the cervix with high-risk HPV infection have not been standardized. Studies show that photodynamic therapy (PDT) mediated by 5-aminolevulinic acid (ALA-PDT) might be effective. In this retrospective study, the clinical efficacy and safety of ALA-PDT in the treatment of LSIL were evaluated.MethodsALA-PDT was performed in 55 LSIL patients aged 21–45 years who also showed high-risk HPV infection and cervical ectropion. HPV test, cytology, colposcopy and pathology were examined before and after treatment. Meanwhile, PDT-related symptoms and adverse reactions were also reviewed.ResultsAt 6-month follow-up after PDT, except for 5 patients who showed the persistence of LSIL lesions, the pathological regression ratio of 90.1% (50/55) was achieved. No HPV-DNA was detected in exfoliated cervical cells in 81.8% (45/55) patients. Among them, the HPV clearance ratio of I Degree cervical ectropion was 96.2%, significantly higher than that of II Degree (70.8%) and III Degree (60%). Significant shrunk of cervical ectropion and reduction of vaginal secretions after PDT were seen in 78.0% patients.ConclusionALA-PDT is a safe and effective therapeutic option for patients of reproductive age who suffer from LSIL with high-risk HPV infection and cervical ectropion.     

Effect and rational application of topical photodynamic therapy (PDT) with 5-aminolevulinic acid (5-ALA) for treatment of cervical intraepithelial neoplasia with vaginal intraepithelial neoplasia

BackgroundLesions in both the cervix and vagina require an efficacious non-invasive treatment therapy such as 5-Aminolevulinic acid photodynamic therapy(5-ALA-PDT). In this study, we evaluate clinical efficacy and safety of 5-ALA PDT for cervical intraepithelial neoplasia with vaginal intraepithelial neoplasia (CIN & VAIN).MethodsA retrospective analysis was performed on 48 patients diagnosed with CIN & VAIN and receiving 5-ALA PDT. All patients were first followed up at 3, 6 and 12 months after treatment, then every 6 months thereafter.ResultsOut of 1051 patients referred for CIN (4.56%), 48 were diagnosed with CIN&VAIIN. The patients had statistically significant average vaginal and cervical lesion areas of 1.22 and 0.41 cm² respectively. 4 patients were lost during follow-up. The patients’ complete remission (CR) rate was 88.64% (39/44) at 3–6 months after treatment, while the total HPV clearance rate was 46.34 and 60.98% at 3- and 12-months follow-up,respectively. HPV16/18 combined with other high-risk human papillomaviruses (hrHPV) (HPV16/18 and other hrHPV) infection exhibited a lower HPV clearance rate (P = 0.006). The treatment time in high-grade intraepithelial neoplasia (HSIL) was higher than that of low-grade intraepithelial neoplasia (LSIL). Notably, atypical vessels and endocervical canal lesions involvement significantly affected 5-ALA PDT. Moreover, 5 patients had residual lesions (11.36%) during follow-up, one patient presented recurrence (2.56%), while 4 had successful pregnancy.Conclusions5-ALA-PDT is a non-invasive, effective, and safe therapy for treating CIN & VAIN and can maintain the structural and functional integrity of target organs. However, its efficacy is relatively poor in patients with endocervical canal lesions involvement, atypical vessels, and HPV16/18 and other hrHPV infection.     

重组人脑利钠肽应用于高龄患者心力衰竭的疗效及安全性

 目的 探讨重组人脑利钠肽(recombinant human brain natriuretic peptide,rhBNP)应用于高龄心力衰竭患者的疗效及安全性。方法 选择2012-01至2017-06就诊于解放军总医院心血管内科的慢性心力衰竭急性发作的高龄患者319例,其中常规治疗+ rhBNP181例(rhBNP组),常规治疗138例(对照组)。比较两组患者治疗后5 d、3个月的B型利钠肽前体水平(NT-proBNP),左室射血分数(left ventricular ejection fraction, LVEF),心室短轴缩短指数(left ventricular short axis reduced index, FS),6分钟步行试验(6 minutes walking test, 6MWT),肝、肾功能及血压的变化,以及再住院率的差异。结果 治疗后5 d,rhBNP组中,NT-proBNP显著降低(P<0.05),LVEF、FS及6MWT结果升高(P<0.05)。治疗后3个月,rhBNP组NT-proBNP较对照组明显降低(P<0.05), LVEF、 FS及6MWT较治疗前改善(P<0.05)。rhBNP组与对照组相比,治疗3个月后再住院率显著降低(P<0.05)。结论 rhBNP治疗高龄患者慢性心力衰竭急性加重安全有效,且能降低3个月内因心力衰竭的再住院率。